Do analysts recommend CLNN or PHXM?

Clene presently has a consensus price target of $34.00, suggesting a potential upside of 692.54%. Given Clene's stronger consensus rating and higher probable upside, analysts clearly believe Clene is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clene 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, CLNN or PHXM?

PHAXIAM Therapeutics has lower revenue, but higher earnings than Clene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clene $197K 282.97 -$26.17M -$3.50 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is CLNN or PHXM more profitable?

PHAXIAM Therapeutics has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Company Net Margins Return on Equity Return on Assets Clene -20,063.96% N/A -137.04% PHAXIAM Therapeutics N/A N/A N/A

Do analysts rate PHXM or VERU?

Veru has a consensus target price of $24.50, indicating a potential upside of 895.93%. Given Veru's stronger consensus rating and higher possible upside, analysts plainly believe Veru is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Veru 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher earnings & valuation, PHXM or VERU?

PHAXIAM Therapeutics has higher earnings, but lower revenue than Veru. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PHAXIAM Therapeutics N/A N/A -$240K N/A N/A Veru $16.89M 2.48 -$22.73M -$0.69 N/A

Is PHXM or VERU more profitable?

PHAXIAM Therapeutics' return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets PHAXIAM Therapeutics N/A N/A N/A Veru N/A -47.58% -35.83%

Do analysts prefer IXHL or PHXM?

Incannex Healthcare presently has a consensus target price of $18.00, indicating a potential upside of 423.26%. Given Incannex Healthcare's stronger consensus rating and higher probable upside, equities analysts clearly believe Incannex Healthcare is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, IXHL or PHXM?

PHAXIAM Therapeutics has lower revenue, but higher earnings than Incannex Healthcare. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incannex Healthcare $90K 457.52 -$46.88M -$1.55 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is IXHL or PHXM more profitable?

PHAXIAM Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -81.01% -76.11% PHAXIAM Therapeutics N/A N/A N/A

Do analysts prefer CRVO or PHXM?

CervoMed presently has a consensus target price of $21.00, indicating a potential upside of 736.65%. Given CervoMed's stronger consensus rating and higher probable upside, equities analysts clearly believe CervoMed is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CervoMed 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, CRVO or PHXM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CervoMed N/A N/A -$26.97M -$3.22 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Which has higher earnings and valuation, KPTI or PHXM?

PHAXIAM Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Karyopharm Therapeutics $146.07M 0.27 -$196.04M -$13.09 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is KPTI or PHXM more profitable?

PHAXIAM Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics -153.28% N/A -145.18% PHAXIAM Therapeutics N/A N/A N/A

PHAXIAM Therapeutics (PHXM) Competitors

$3.10 0.00 (0.00%)

As of 09/22/2026

Compare

PHXM vs. CLNN, VERU, IXHL, CRVO, and KPTI

Should you buy PHAXIAM Therapeutics stock or one of its competitors? PHAXIAM Therapeutics's main competitors and comparable companies include Clene (CLNN), Veru (VERU), Incannex Healthcare (IXHL), CervoMed (CRVO), and Karyopharm Therapeutics (KPTI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does PHAXIAM Therapeutics compare to Clene?

Clene (NASDAQ:CLNN) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

Clene has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market.

23.3% of Clene shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 28.3% of Clene shares are owned by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Clene had 3 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 3 mentions for Clene and 0 mentions for PHAXIAM Therapeutics. PHAXIAM Therapeutics' average media sentiment score of 0.00 beat Clene's score of -0.24 indicating that PHAXIAM Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Clene	Neutral
PHAXIAM Therapeutics	Neutral

PHAXIAM Therapeutics has a net margin of 0.00% compared to Clene's net margin of -20,063.96%.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-20,063.96%	N/A	-137.04%
PHAXIAM Therapeutics	N/A	N/A	N/A

PHAXIAM Therapeutics has lower revenue, but higher earnings than Clene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$197K	282.97	-$26.17M	-$3.50	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Clene presently has a consensus price target of $34.00, suggesting a potential upside of 692.54%. Given Clene's stronger consensus rating and higher probable upside, analysts clearly believe Clene is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Clene beats PHAXIAM Therapeutics on 7 of the 12 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Veru?

PHAXIAM Therapeutics (NASDAQ:PHXM) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

In the previous week, Veru had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for Veru and 0 mentions for PHAXIAM Therapeutics. PHAXIAM Therapeutics' average media sentiment score of 0.00 equaled Veru'saverage media sentiment score.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
Veru	Neutral

0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Comparatively, 14.2% of Veru shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Veru has a consensus target price of $24.50, indicating a potential upside of 895.93%. Given Veru's stronger consensus rating and higher possible upside, analysts plainly believe Veru is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

PHAXIAM Therapeutics has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market. Comparatively, Veru has a beta of -1.17, meaning that its share price is 217% less volatile than the broader market.

PHAXIAM Therapeutics has higher earnings, but lower revenue than Veru.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
Veru	$16.89M	2.48	-$22.73M	-$0.69	N/A

PHAXIAM Therapeutics' return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
Veru	N/A	-47.58%	-35.83%

Summary

Veru beats PHAXIAM Therapeutics on 7 of the 11 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Incannex Healthcare's average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score.

Company	Overall Sentiment
Incannex Healthcare	Neutral
PHAXIAM Therapeutics	Neutral

Incannex Healthcare presently has a consensus target price of $18.00, indicating a potential upside of 423.26%. Given Incannex Healthcare's stronger consensus rating and higher probable upside, equities analysts clearly believe Incannex Healthcare is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PHAXIAM Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
PHAXIAM Therapeutics	N/A	N/A	N/A

PHAXIAM Therapeutics has lower revenue, but higher earnings than Incannex Healthcare.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	457.52	-$46.88M	-$1.55	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Incannex Healthcare has a beta of 6.97, suggesting that its share price is 597% more volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market.

Summary

Incannex Healthcare beats PHAXIAM Therapeutics on 6 of the 10 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to CervoMed?

CervoMed (NASDAQ:CRVO) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

25.1% of CervoMed shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 35.8% of CervoMed shares are held by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, CervoMed had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for CervoMed and 0 mentions for PHAXIAM Therapeutics. CervoMed's average media sentiment score of 0.99 beat PHAXIAM Therapeutics' score of 0.00 indicating that CervoMed is being referred to more favorably in the media.

Company	Overall Sentiment
CervoMed	Positive
PHAXIAM Therapeutics	Neutral

CervoMed has a beta of -0.64, suggesting that its share price is 164% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market.

CervoMed presently has a consensus target price of $21.00, indicating a potential upside of 736.65%. Given CervoMed's stronger consensus rating and higher probable upside, equities analysts clearly believe CervoMed is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PHAXIAM Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. PHAXIAM Therapeutics' return on equity of 0.00% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-156.02%	-128.34%
PHAXIAM Therapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	N/A	N/A	-$26.97M	-$3.22	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Summary

CervoMed beats PHAXIAM Therapeutics on 8 of the 13 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Karyopharm Therapeutics presently has a consensus price target of $11.50, indicating a potential upside of 557.14%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Karyopharm Therapeutics is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Karyopharm Therapeutics had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for Karyopharm Therapeutics and 0 mentions for PHAXIAM Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score.

Company	Overall Sentiment
Karyopharm Therapeutics	Neutral
PHAXIAM Therapeutics	Neutral

Karyopharm Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market.

66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PHAXIAM Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-153.28%	N/A	-145.18%
PHAXIAM Therapeutics	N/A	N/A	N/A

PHAXIAM Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	0.27	-$196.04M	-$13.09	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Summary

Karyopharm Therapeutics beats PHAXIAM Therapeutics on 7 of the 12 factors compared between the two stocks.

Get PHAXIAM Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHXM vs. The Competition

Export

Metric	PHAXIAM Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.58M	$12.61B	$7.31B	$13.28B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	N/A	792.28	274.10	25.70
Price / Sales	N/A	857.09	672.61	90.85
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	0.39	10.57	10.48	6.32
Net Income	-$240K	$2.81B	$3.49B	$359.73M
7 Day Performance	N/A	-0.17%	-0.68%	0.17%
1 Month Performance	N/A	-1.39%	-3.18%	-3.27%
1 Year Performance	N/A	2.83%	15.13%	5.58%

PHAXIAM Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
CLNN Clene	1.9164 of 5 stars	$4.02 +22.6%	$34.00 +745.8%	-29.9%	$42.14M	$200K	N/A	100	High Trading Volume
VERU Veru	2.2261 of 5 stars	$2.34 flat	$24.50 +947.0%	-27.0%	$39.90M	N/A	N/A	230
IXHL Incannex Healthcare	1.6527 of 5 stars	$3.45 +4.9%	$18.00 +421.7%	-82.9%	$39.36M	$90K	N/A	3
CRVO CervoMed	2.6823 of 5 stars	$2.45 -3.2%	$21.00 +757.1%	-69.5%	$38.25M	$4.01M	N/A	4	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHXM) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PHAXIAM Therapeutics (PHXM) Competitors

PHXM vs. CLNN, VERU, IXHL, CRVO, and KPTI

How does PHAXIAM Therapeutics compare to Clene?

Summary

How does PHAXIAM Therapeutics compare to Veru?

Summary

How does PHAXIAM Therapeutics compare to Incannex Healthcare?

Summary

How does PHAXIAM Therapeutics compare to CervoMed?

Summary

How does PHAXIAM Therapeutics compare to Karyopharm Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHXM vs. The Competition

PHAXIAM Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PHAXIAM Therapeutics (PHXM) Competitors

PHXM vs. CLNN, VERU, IXHL, CRVO, and KPTI

How does PHAXIAM Therapeutics compare to Clene?

Which has more risk and volatility, CLNN or PHXM?

Do insiders & institutionals hold more shares of CLNN or PHXM?

Does the media refer more to CLNN or PHXM?

Is CLNN or PHXM more profitable?

Which has higher earnings & valuation, CLNN or PHXM?

Do analysts recommend CLNN or PHXM?

Summary

How does PHAXIAM Therapeutics compare to Veru?

Does the media favor PHXM or VERU?

Do institutionals and insiders believe in PHXM or VERU?

Do analysts rate PHXM or VERU?

Which has more volatility & risk, PHXM or VERU?

Which has higher earnings & valuation, PHXM or VERU?

Is PHXM or VERU more profitable?

Summary

How does PHAXIAM Therapeutics compare to Incannex Healthcare?

Do insiders and institutionals believe in IXHL or PHXM?

Does the media refer more to IXHL or PHXM?

Do analysts prefer IXHL or PHXM?

Is IXHL or PHXM more profitable?

Which has stronger earnings & valuation, IXHL or PHXM?

Which has more risk & volatility, IXHL or PHXM?

Summary

How does PHAXIAM Therapeutics compare to CervoMed?

Do insiders and institutionals believe in CRVO or PHXM?

Does the media refer more to CRVO or PHXM?

Which has more risk & volatility, CRVO or PHXM?

Do analysts prefer CRVO or PHXM?

Is CRVO or PHXM more profitable?

Which has stronger earnings & valuation, CRVO or PHXM?

Summary

How does PHAXIAM Therapeutics compare to Karyopharm Therapeutics?

Do analysts prefer KPTI or PHXM?

Does the media refer more to KPTI or PHXM?

Which has more volatility and risk, KPTI or PHXM?

Do institutionals and insiders believe in KPTI or PHXM?

Is KPTI or PHXM more profitable?

Which has higher earnings and valuation, KPTI or PHXM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHXM vs. The Competition

PHAXIAM Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools